Open AccessIL‐6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL‐2
Author(s) -
YANAGAWA H.,
SONE S.,
MUNEKATA M.,
ATAGI S.,
NII A.,
OGURA T.
Publication year - 1992
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1992.tb03063.x
Subject(s) - medicine , malignant pleural effusion , pleurisy , pleural effusion , respiratory disease , pleural disease , lung cancer , effusion , lung , pathology , immunology , surgery
SUMMARY The levels and activities of endogenous IL‐6 in malignant pleural effusions due to lung cancer before and during daily intrapleural instillations of recombinant IL‐2 were examined by enzyme immunoassay and bioassay using an IL‐6‐dependent murine hybridoma cell line MH60.BSF2. Before therapy, malignant pleural effusions contained various levels of IL‐6. Daily intrapleural instillation of recombinant IL‐2 for treatment of malignant pleurisy resulted in significant augmentation of the levels and activities of IL‐6 in the pleural effusions. On fractionation of the pleural effusion by chromatography. one major peak of material with a mol. wt of 24 kD showed IL‐6 activity. In contrast, no significant level of tumour necrosis factor‐alpha or IL‐1β was detectable in pleural effusions before or during local IL‐2 therapy. These data suggest that IL‐2 is an important regulatory factor of secondary IL‐6 production.